• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar

Stock Trend Alerts

Essential Market Ideas and Investing Strategies

  • Financial Newsletter Reviews
  • Hot Stocks
  • Technology
  • Financial News
  • Secrets of the Pros
  • Analysis
Home » These Stocks are Down, But they’re Definitely Not Out

These Stocks are Down, But they’re Definitely Not Out

In this Article:

  • The market is forward-looking
  • A good margin of safety
  • An especially rough year

Always look on the bright side. Not only does this put you in a better mood, but it also can help you make money. That's especially true in the current stock market downturn.

We asked three Motley Fool contributors to pick beaten-down stocks to buy right now. Here's why they chose Moderna (MRNA), Pfizer (PFE), and Zoetis (ZTS).

Look beyond the pandemic

Prosper Junior Bakiny (Moderna): The market is forward-looking. Right now, it sees trouble ahead for companies that rely partly or exclusively on their coronavirus vaccines or medicines to generate revenue. Moderna fits the bill, which is why its shares have dropped substantially this year. Starting in 2023, the company's sales will suffer. To be clear, though, Moderna's revenue won't drop to zero as COVID-19 is almost definitely here to stay. 

The biotech has one of the most successful vaccines on the market, and it has targeted variants of the coronavirus with newer versions of its crown jewel. Moderna will remain a leader in the coronavirus booster market.

Equally as important, though, investors should try to look beyond next year. Moderna is generating lots of cash thanks to its coronavirus portfolio; it had $17 billion in cash and equivalents as of Sept. 30. That will allow it to advance its pipeline.

[Alert: Putin Just Screwed Up Royally… Even For Him]

NASDAQ: MRNA

Source: fool.com

The company has well over a dozen non-COVID candidates, including three that have reached late-stage studies: potential vaccines for flu, cytomegalovirus, and respiratory syncytial virus. Moderna's messenger RNA (mRNA) approach has an advantage because vaccines of this type tend to be faster to manufacture.  

Although we shouldn't expect Moderna to be as fast to launch its next products on the market as it was during the COVID outbreak, the company looks set to record important clinical and regulatory wins in the next five years. It should also continue to advance its ambitious early-stage programs such as its vaccines for HIV and vaccines that target various cancers.

Will the company's programs always pan out? Probably not. But with a diverse pipeline and the funds to carry them to approval, Moderna's future still looks bright, despite its poor performance on the stock market this year. 

[Exclusive: Collect Thousands From America’s Fastest-Growing Firms]

A big margin of safety

David Jagielski (Pfizer): Having a good margin of safety is something you'll often hear billionaire investors Warren Buffett and Charlie Munger talk about. It's all about giving yourself a buffer between where an investment is valued today versus where you think it ought to be. Pfizer stands out as one stock that I think has a potentially significant buffer.

Shares of this top healthcare company are down close to 20% this year and trade at just nine times trailing earnings. By comparison, the average healthcare stock trades at a multiple of nearly 22. There's a huge buffer there to suggest that even if Pfizer's earnings were to be cut in half, it could still be a good buy.

NYSE: PFE

Source: fool.com

Investors are clearly bracing for a sharp decline in revenue. With COVID-19 revenue totaling $56 billion and accounting for over half of Pfizer's business this year, a drop-off could be likely as people become less concerned about the coronavirus.

But that's a big assumption since there are concerns that COVID cases could spike this winter. The U.S. government is also looking at whether Pfizer's pill Paxlovid could be an effective treatment for long COVID.

Even if there's a drop-off, it likely won't be as steep as what investors are pricing into the stock's valuation right now. And Pfizer hasn't been sitting idle. It has been making moves to acquire businesses that can improve its long-term potential, including the recent acquisitions of Global Blood Therapeutics (for sickle cell treatment) and Biohaven Pharmaceuticals (migraine therapy).

Pfizer's business is facing some challenges: It will undoubtedly lose some revenue from COVID treatments and products that are losing exclusivity later this decade. But the bearishness surrounding the stock seems to be excessive. This is a company that quickly formulated a coronavirus vaccine, proving how fast it can adapt to change and bring a product to market.

Investors shouldn't dismiss the company's track record for growth. Although there's some risk ahead for the business, there's also plenty of margin of safety at its current valuation to make Pfizer a good stock to buy right now.

[Don't Miss: Crypto Millionaire Abandons Bitcoin After Crash For THIS]

A global leader with bright long-term prospects

Keith Speights (Zoetis): It's been an especially rough year for Zoetis. Shares of the animal health company have plunged more than 40%. It has faced several headwinds, including supply chain issues, staffing challenges in veterinarians' offices, and the strong U.S. dollar.

NYSE: ZTS

Source: fool.com

But the long-term prospects for Zoetis remain bright. More than 60% of the company's total revenue comes from products for companion animals. This market should expand significantly as more people adopt pets and spend on the animals' health.

Zoetis' livestock business should also be a solid growth opportunity. The demand for protein in emerging markets, notably China, appears likely to increase as overall income levels grow.

No company is in as strong a position to profit from these trends as Zoetis. It currently ranks as the global market leader in animal health for companion animals, cattle, fish, and swine. And it is No. 5 worldwide in the poultry market.

The company has delivered market-beating revenue growth in recent years. CEO Kristin Peck said in the third-quarter conference call that Zoetis has “the pipeline, market leadership positions, global scale, and financial strength to continue outpacing the market.”

I think she's right. Wall Street seems to believe so, too: The consensus 12-month price target reflects an upside potential of more than 50% for this beaten-down stock.

[Alexander Green: The New King of LNG]

Read more from Keith Speights, David Jagielski, and Prosper Junior Bakiny at Fool.com

You Might Also Like...

  • The Top Industrial Stocks for Long Term Investors
  • The Top 10 Stocks For 2023
  • Big Gains In Tiny sector
  • The Best Retirement Stocks for Long-Term Growth and Income

Reader Interactions

Leave a Reply Cancel reply

Your email address will not be published. Required fields are marked *

This site uses Akismet to reduce spam. Learn how your comment data is processed.

Primary Sidebar

Subscribe to Stock Trend Alerts

By submitting your email address, you give Stock Trend Alerts permission to deliver investment research to your email inbox. Privacy Policy | How It Works

Popular Posts

  • Elon Musk’s “Project Omega” and Top 3 Stocks for the AI Revolution
  • Marc Chaikin Reveals Biggest Stock Prediction of his 50-year Career on Wall Street
  • Marc Chaikin’s AI Power Picks: #1 Free AI Stock Recommendation Revealed
  • Infinite Energy Stock: The Tiny Company Dominating Tesla in the Trillion-Dollar Green Energy Race
  • “Imperium” The Next Intel: The Microchip Company Powering the 199,000% DNA Mega Trend
  • Ross Givens: The $3 AI Wonder Stock that Could Make You 75X Richer in 2023
  • Full Review: Elon Musk’s “Project Omega”
  • Andrew Zatlin Moneyball Economics: The FedNow Profit Report #1 Stock

Recent Posts

  • The No. 1 x.AI Company Working to Eradicate Cancer: NGS Fortunes
  • The $100 AI Jackpot: How To Target Potentially Huge Profits With 3 Tiny AI Stocks
  • Elon Musk’s New (Secret) AI Facility Revealed by Teeka Tiwari
  • 3 Inflation-Beating Stocks to Buy Now and 5 Ways to Protect Your Money Starting Today
  • Whitney Tilson’s Perfect Portfolio: How to Profit From the $87 Trillion AI Wave

Topics

Advertorial Amazon AMZN Apple Artificial Intelligence Banking Battery Bear Market Biotech Bitcoin Blockchain China Clean Energy Cloud Computing Coronavirus COVID Creative Cryptocurrency Dividends Electric Vehicles Elon Musk Energy Ethereum Gold Google Inflation Interest Rates International Jeff Brown Louis Navellier Market Crash Microsoft Nomi Prins Oil and Gas Options President Biden Recession Retirement Semiconductor Supply Chain Tesla The Fed TSLA Volatility Warren Buffett

Copyright © 2023 · Stock Trend Alerts - Essential Market Moves and Investing Ideas

Nothing on this website should be considered personalized financial advice. Any investments recommended here in should be made only after consulting with your personal investment advisor and only after performing your own research and due diligence, including reviewing the prospectus or financial statements of the issuer of any security.

Stock Trend Alerts, its managers, its employees, affiliates and assigns (collectively "The Company") do not make any guarantee or warranty about the advice provided on this website or what is otherwise advertised above.

The Company is not registered or licensed by any governing body in any jurisdiction to give investing advice or provide investment recommendation. The Company is not affiliated with, nor does it receive compensation from, any specific security.

To the maximum extent permitted by law, the Company disclaims any and all liability in the event any information, commentary, analysis, opinions, advice and/or recommendations provided herein prove to be inaccurate, incomplete or unreliable, or result in any investment or other losses.

About Us | How it Works | Privacy Policy | Terms and Conditions | Contact Us